Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2012 - 2026)

Ptc Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $83.5 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 228.75% year-over-year to $83.5 million; the TTM figure through Jun 2026 stood at $382.5 million (down 39.21% YoY), while the FY2025 annual figure was $1.0 billion, up 377.05% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at $83.5 million, up from -$2.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $866.6 million in Q1 2025, with the low at -$198.9 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$102.9 million (2024), against an average of -$20.3 million.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders surged 1046.28% in 2025, then sank 100.32% in 2026.
• Ptc Therapeutics' Net Income towards Common Stockholders stood at -$170.9 million in 2022, then increased by 8.83% to -$155.8 million in 2023, then surged by 57.71% to -$65.9 million in 2024, then surged by 533.96% to $285.9 million in 2025, then plunged by 70.8% to $83.5 million in 2026.
• Business Quant data shows PTCT's Net Income towards Common Stockholders at $83.5 million in Q2 2026, -$2.8 million in Q1 2026, and $285.9 million in Q4 2025.